TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Neurotropin to Treat Chronic Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~CRPS patients are referred with a diagnosis of CRPS-I or CRPS-II in one limb only, based on pain (1) that is post-traumatic and spread beyond the region of the injury; (2) has persisted for more than 2 weeks; and (3) is associated with swelling, altered skin color or skin temperature, altered sweating, allodynia or hyperesthesia or limitation of active movement. Atrophic changes in skin, hair loss or nail changes, or disuse atrophy of skeletal muscle may be present.~Both sexes are to be studied.~All ethnic and racial groups can participate.~Patients must be willing to return to NIH for follow-up evaluation under this protocol.~EXCLUSION CRITERIA:~Pregnant and lactating women are excluded.~Based on the oral surgeon's postoperative diagnosis, any extraction which is classified as producing unusual surgical trauma will result in exclusion from the remainder of the study.~Dental subjects will also be excluded if they are not adequately sedated by midazolam alone and require intraoperative administration of an opioid drug such as fentanyl, administration of greater than 14.4 ml of local anesthetic (2% lidocaine with 1:100,000 epinephrine), or postoperative administration of a steroid for possible injury to the inferior alveolar nerve.~Patients referred with CRPS-I or CRPS II who have abnormal screening test results or who have non-traumatic disorders to which pain may be attributed (gout, malignancy, arthritis, etc.) will be excluded.~Any patients who have had ablative procedures for treatment of their neuropathic pain disorder will not be eligible for inclusion in this study.~Patients who have a positive HIV result will be excluded.~Subjects with obviously impaired mental capacity that precludes informed consent and ability to provide adequate self-ratings are to be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo first, then Neurotropin (G-1) (Type: ACTIVE_COMPARATOR): Double blind cross-over study: receive placebo for 5 weeks and then Neurotropin for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
- Neurotropin first, then Placebo (G-2) (Type: ACTIVE_COMPARATOR): Double blind cross-over study: receive Neurotropin for 5 weeks and then placebo for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Mineral Trioxide Aggregate (MTA) & Ferric Sulfate (FS) Pulpotomies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I,II~* Primary Molars diagnosed with normal or reversible pulpitis with vital carious pulp exposures~* Teeth that can have hemostasis can be achieved with pressure~* No clinical symptoms~* No radiographic signs of internal resorption or external root resorption~Exclusion Criteria:~* Primary Molars diagnosed with irreversible pulpitis or necrotic pulp~* Teeth that can not achieve hemostasis~* Teeth with abscess or fistula~* Teeth that have radiographic signs of internal resorption or external resorption

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Mineral Trioxide Aggregate (Type: EXPERIMENTAL): Subject with pulpotomy treated with MTA MTA paste (\< 1gm) will be placed on pulp orifice once for the life of the primary teeth
- Ferric Sulfate (Type: EXPERIMENTAL): Subject with pulpotomy treated with FS FS paste (\<1gm) will placed on pulp orifice once for 15 secs and removed on primary teeth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Junior Emergency Physician Learning Curve to Perform Transcranial Doppler on Brain-damage Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients : ≥ 18 year and older~* Hospitalized in the neurosurgical resuscitation or intensive care unit~* Brain - damaged patients~Exclusion Criteria:~* Any craniotemporal lesion impeding satisfactory TDC examination : no transtemporal doppler window, patient with craniectomy.~* Patient with meningo-encephalitis~* Patient with cerebral vasculitis~* Patient without health insurance coverage~* Patient subject to a legal protection measure~* Pregnant woman , parturient or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants aged at least 18 y/o diagnosed with ADHD by Diagnostic and Statistical Manual of Mental Disorders (DSM)~* Participants with a lower than 0 TOVA score or with a higher than 0 score whom as per investigator opinion suffer from ADHD~* Participants who experienced treatment failure with more than one ADHD conventional drug~* Participants willing to attend all the visits in the trial.~Exclusion Criteria:~* Participants who were treated with benzodiazepines, antihistamines, etc, in the week that preceded the trial start.~* Participants suffering from neurologic or psychiatric diseases~* Participants suffering from malignant diseases~* Participants suffering from syndromes or metabolic diseases~* Participants with significant clinical diagnosis that can damage the trial unfolding. The investigator may include them after the end of the situation which prevented their previous inclusion.~* Participants breastfeeding, pregnant or not willing to use contraceptives.~* Participants that will not adhere to the protocol as per investigator opinion~* Participants who weight less than 45 kg or more than 120kg or with BMI greater than 30~* Participants participating in another clinical trial which includes drug treatment~* Participants receiving any treatment for ADHD~* Participants using drugs~* Participants using cannabis or products containing cannabinoids, including medical cannabis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CBD rich (Type: EXPERIMENTAL): Cannabis oil oral drops containing 95 mg/ml CBD; 5 mg/ml THC; 15 mg/ml CBDV ; no CBG, once daily Titration from 0.3 to 1.8 ml/day during 21 days
- CBG rich (Type: EXPERIMENTAL): Cannabis oil oral drops containing no CBD; 5 mg/ml THC; no CBDV; 95 mg/ml CBG, once daily.~Titration from 0.3 to 1.8 ml/day during 21 days
- CBD & CBG rich (Type: EXPERIMENTAL): Cannabis oil oral drops containing 47.5 mg/ml CBD; 2.5 mg/ml THC; 7.5 mg/ml CBDV; 47.5 mg/ml CBG, once daily.~Titration from 0.3 to 1.8 ml/day during 21 days
- placebo (Type: PLACEBO_COMPARATOR): Placebo oil oral drops once daily. Titration from 0.3 to 1.8 ml/day during 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed recurrent or extensive stage small cell lung cancer unlikely to have a curative response to existing standard regimens~* Measurable disease by MRI or CT scan~  * At least 2 cm in diameter~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal insufficiency~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No severe heart disease~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease (e.g., chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No active infections~* No other concurrent serious disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* No prior antineoplaston therapy~* Prior cytodifferentiating agent allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of and/or documented fever (rectal, ear, or oral temperature ≥38°C or axillary temperature ≥37.5°C) or hypothermia (rectal, ear, or oral temperature \<35°C or axillary temperature \<34.5°C)~* Chest radiograph infiltrates consistent with bacterial pneumonia (or pneumonia caused by atypical bacterial agents); if a subject is outpatient and starting on oral therapy, a radiograph is not required.~* Presence of at least 2 of the following signs or symptoms:~* Cough~* Difficulty breathing~* Production of purulent sputum~* Chest pain~* Grunting~* Hypotension~* Tachycardia, defined as follows:~  2 months to \<24 months: ≥160 beats/min 24 months to \<10 years: ≥140 beats/min~ * 10 years: ≥100 beats/min~* Tachypnea, defined as follows:~  2 months to \<12 months: ≥50 breaths/min 12 months to \<5 years: ≥40 breaths/min~ * 5 years: ≥20 breaths/min~* Physical exam consistent with pulmonary consolidation~* Presence of at least 1 of the following:~* Leukocytosis (≥12,000 white blood cells \[WBC\]/mm3)~* Leukopenia (\<5000 WBC/mm3)~* ≥10% immature neutrophils (bands) regardless of total peripheral WBC~* Elevated inflammatory markers (C-reactive protein or procalcitonin)~* Oxygen saturation \<97% on room air~* Organism consistent with a typical respiratory pathogen identified~Exclusion Criteria:~* Ventilator-associated or hospital-acquired pneumonia~* \>48 hours of systemic antibacterial therapy~* confirmed or suspected bacterial meningitis~* breast-feeding females~* positive pregnancy test

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Solithromycin (Type: EXPERIMENTAL): Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
- Standard of Care (Type: ACTIVE_COMPARATOR): Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is \</= 70 years of age and requires isolated aortic valve replacement with or without concomitant procedures such as coronary artery bypass or another valve reconstruction. (The three remaining valves must be of native tissue).~* Patient is sufficiently ill to warrant replacement of his/her diseased natural or prosthetic valve (excluding the ATS 3f Aortic Bioprosthesis, Model 1000 bioprosthesis), based on standard cardiovascular diagnostic workups.~* Patient is in satisfactory condition, based on the physical exam and Investigator's experience, to be an average or better operative risk, (i.e., likely to survive three years postoperatively).~* Patient is geographically stable and willing to return to the implant center for follow-up visits.~* Patient has been adequately informed and consents to his/her participation in the clinical study, and of what will be required of him/her, in order to comply with the protocol.~Exclusion Criteria:~* Patient is older than seventy (70) years of age.~* Patient has a non-cardiac major or progressive disease, which in the Investigator's experience produces an unacceptable increased risk to the patient, or results in a life expectancy of less than 3 years.~* Patient is an intravenous drug and/or alcohol abuser.~* Female patient is pregnant (urine HCG test result positive), or lactating.~* Patient presents with active endocarditis.~* Patient presents with congenital bicuspid aortic anatomy.~* This patient presents with abnormal aortic root geometry.~* Patient has chronic renal failure or is on renal dialysis.~* Patient has a previously implanted prosthetic valve that is not being replaced by a study valve.~* Patient requires mitral, tricuspid or pulmonic valve replacement.~* Patient presents with dilatation of the ascending aorta, Marfan Syndrome, Ehlers-Danlos syndrome, cystic medial degeneration, or other condition causing the ascending aorta to be irregular in geometry or physiology as seen via preoperative imaging.~* Patient is participating in concomitant research studies of investigational products.~* Patient will not agree to return to the implant center for the required number of follow-up visits or is geographically unavailable for follow-up.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ATS 3f Aortic Bioprosthesis (Type: OTHER): ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Undergoing routine prostatectomy or transurethral resection of the prostate (TURP)~PATIENT CHARACTERISTICS:~5.1.1 Patient is undergoing routine prostatectomy or TURP.~5.1.2 Patient is ≥ 18 years old.~5.1.3 Patient must give informed consent.~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Sexual Dysfunction in Gynecologic Oncology Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Female~* Age 18-99~* Planned to undergo primary surgical treatment at the University of Iowa Hospitals and Clinics for a suspected or proven diagnosis of ovarian, fallopian tube, peritoneal, endometrial, or cervical cancer~* Able to give informed consent and follow study procedures~* No previous reactions to lidocaine applications~* Performance Status of 0 or 1~* Reports having engaged in vaginal intercourse at least once in the last 12 months~Exclusion criteria:~* Failure to confirm invasive ovarian, fallopian tube, peritoneal, endometrial or cervical cancer by pathology from primary biopsy or surgery (subjects will not be eligible to continue the trial beyond the initial completion of the questionnaires)~* Diagnosis of another malignancy within the past five years, excluding basal cell carcinoma of the skin~* Patients undergoing primary or adjuvant external pelvic radiation (excluding adjuvant vaginal brachytherapy)~* Previous reactions to lidocaine applications~* Previous reactions to lidocaine for the subjects' sexual partner(s)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters.
- Placebo (Type: PLACEBO_COMPARATOR): Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Short-term Perfusion Angiography Pilot Study (SPA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject is ≥ 18 years of age.~2. Subject or their legally authorized representative understands the research nature of the study and is willing and capable of providing informed consent~3. Subject has appropriate femoral arterial access~4. Subject presents with a Rutherford classification of 4 to 6.~5. Planned DSA with endovascular intervention below the knee on one or both limbs. This may include patients who undergo:~   1. Above the knee (ATK) and below the knee (BTK) intervention during the same procedure.~  2. Only BTK intervention.~  3. ATK intervention with staged future BTK intervention within 6 weeks of the initial procedure.~Exclusion Criteria:~1. Subjects whose ATK intervention is limited to only the common femoral or iliac arteries~2. Subject is unwilling or unable to comply with the protocol including all follow-up visits~3. Subject with active atrial fibrillation at time of procedure~4. Critical limb ischemia due to acute arterial occlusion.~5. Subject with documented ejection fraction \< 40% and/or prolonged bradycardia (\< 60 beats per minute)~6. Inability to collect toe pressure on index limb from subject~7. Subjects with history of or known reaction or sensitivity to contrast agent that cannot be pre-medicated or any other condition that precludes an endovascular intervention and DSA~8. Female subject of childbearing potential who is pregnant (she must have negative pregnancy test within the 48 hours prior to enrollment), or plans a pregnancy during study period,~9. Subject life expectancy \< 3 months,~10. Subject is participating in a potentially confounding device or drug clinical trial that interferes with this study~11. Investigator considers subject to be a poor candidate for the study or believes that the patient may compromise the study, e.g., concomitant conditions (reasons will be documented) )

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Subjects aged 18 to 75 years with a diagnosis of CD for at least 3 months;~2. Moderately to severely active CD as defined by: a CDAI score of 220 450, and an SES-CD scored ≥ 6 ( ≥ 4 for isolated ileitis) (centrally read);~Key exclusion criteria:~1. Ulcerative colitis;~2. Known current bacterial or parasitic pathogenic enteric infection; live virus vaccination within 12 weeks of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BT-11 880 mg (Type: EXPERIMENTAL): Oral once daily tablet
- Placebo (Type: PLACEBO_COMPARATOR): Oral once daily tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy